Summaries & Associations of Study Results
TR-450 Tetrafluoroethylene
Target Organs and Levels of Evidence
NTP Technical Report Number 450
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| TETRAFLUOROETHYLENE 116-14-3 |
12/05/95 | MONOMER FOR POLYTETRAFLUOROETHYLENE POLYMERS. PREPARATION OF PROPELLANTS FOR FOOD PRODUCT AEROSOLS. CHEMICAL INTERMEDIATE. (TDB) | Inhalation MICE & FR: 0, 312, 625, OR 1250 MR: 0, 156, 312, OR 625 PPM; 50/GROUP | Battelle Northwest Laboratory |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: CLEAR EVIDENCE | KIDNEY TUBULAR CELL: SINGLE SECTIONS: ADENOMA 0/50 0/50 6/50 3/50 OR CARCINOMA 1/50 0/50 2/50 0/50 COMBINED 1/50 0/50 6/50 3/50; SINGLE AND STEP SECTIONS: ADENOMA 2/50 4/50 9/50 13/50 OR CARCINOMA 1/50 1/50 2/50 0/50 COMBINED 3/50 5/50 9/50 13/50 | |||
| LIVER: ADENOMA 3/50 6/50 8/50 5/50 OR CARCINOMA 1/50 1/50 10/50 3/50 COMBINED 4/50 7/50 15/50 8/50 | ||||
| MAY HAVE BEEN RELATED: | HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA: 34/50 43/50 38/50 31/50 | |||
| TESTIS: INTERSTITIAL CELL ADENOMA 39/50 40/50 48/50 47/50 | ||||
| NON-NEOPLASTIC LESIONS: | KIDNEY: INCREASED SEVERITY OF NEPHROPATHY; TUBULE DEGENERATION; TUBULE HYPERPLASIA | |||
| FR: CLEAR EVIDENCE | KIDNEY TUBULAR CELL: SINGLE SECTIONS: ADENOMA 0/50 3/50 1/50 3/50 OR CARCINOMA 0/50 0/50 0/50 2/50 COMBINED 0/50 3/50 1/50 5/50; SINGLE AND STEP SECTIONS: ADENOMA 0/50 3/50 3/50 8/50 OR CARCINOMA 0/50 0/50 0/50 3/50 COMBINED 0/50 3/50 3/50 10/50 | |||
| LIVER: ADENOMA 0/50 4/50 5/50 6/50 OR CARCINOMA 0/50 4/50 9/50 2/50 COMBINED 0/50 7/50 12/50 8/50 | ||||
| HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA: 16/50 31/50 23/50 36/50 | ||||
| VASCULAR SYSTEM (LIVER): HEMANGIOSARCOMA 0/50 0/50 5/50 1/50 | ||||
| NON-NEOPLASTIC LESIONS: | KIDNEY: TUBULE DEGENERATION; TUBULE HYPERPLASIA | |||
| LIVER: ANGIECTASIS | ||||
| EYE: CATARACTS | ||||
| MM: CLEAR EVIDENCE | LIVER: ADENOMA 17/48 17/48 12/48 20/48 OR CARCINOMA 11/48 20/48 33/48 26/48 COMBINED 26/48 34/48 39/48 35/48 | |||
| HEMATOPOIETIC SYSTEM: HISTIOCYTIC SARCOMA 0/48 12/48 7/48 7/48 | ||||
| VASCULAR SYSTEM (LIVER): HEMANGIOMA 0/48 10/48 5/48 2/48 OR HEMANGIOSARCOMA 0/48 21/48 27/48 37/48 COMBINED 0/48 26/48 30/48 38/48 | ||||
| NON-NEOPLASTIC LESIONS: | KIDNEY: TUBULE DILATATION; TUBULE KARYOMEGALY | |||
| LIVER: ANGIECTASIS | ||||
| SPLEEN: HEMATOPOIETIC CELL PROLIFERATION | ||||
| FM: CLEAR EVIDENCE | LIVER: ADENOMA 15/48 17/48 20/47 15/47 OR CARCINOMA 4/48 28/48 22/47 20/47 COMBINED 17/48 33/48 29/47 28/47 | |||
| HEMATOPOIETIC SYSTEM: HISTIOCYTIC SARCOMA 1/48 21/48 19/47 18/48 | ||||
| VASCULAR SYSTEM (LIVER): HEMANGIOMA 0/48 5/48 2/47 1/47 OR HEMANGIOSARCOMA 0/48 27/48 27/47 34/47 COMBINED 0/48 31/48 28/47 35/47 | ||||
| NON-NEOPLASTIC LESIONS: | KIDNEY: TUBULE KARYOMEGALY | |||
| LIVER: ANGIECTASIS; HEMATOPOIETIC CELL PROLIFERATION | ||||
| SPLEEN: HEMATOPOIETIC CELL PROLIFERATION | ||||
Web page last updated on February 10, 2006
